Mark Kosins
Psychiatry · San Clemente, CANPI 1457424954
Payments from drug & device makers
Across 268 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lundbeck LLC$750
- Takeda Pharmaceuticals U.S.A., Inc.$563
- Vanda Pharmaceuticals Inc.$374
- Sunovion Pharmaceuticals Inc.$191
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$188
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 103 | $1,512 |
| Lundbeck LLC | 40 | $750 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $563 |
| Vanda Pharmaceuticals Inc. | 17 | $374 |
| Sunovion Pharmaceuticals Inc. | 8 | $191 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $188 |
| Ironshore Pharmaceuticals Inc. | 10 | $161 |
| Almatica Pharma LLC | 8 | $160 |
| Alkermes, Inc. | 8 | $147 |
| Idorsia Pharmaceuticals US Inc | 7 | $137 |
| Supernus Pharmaceuticals, Inc. | 6 | $87 |
| Harmony Biosciences LLC | 3 | $77 |
| Johnson & Johnson | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 3 | $70 |
| Vertical Pharmaceuticals, LLC | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Corium, LLC | 2 | $38 |
| Eisai Inc. | 1 | $25 |
| Gilead | 1 | $24 |
| Tris Pharma Inc | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
How this compares
$4,754 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 19 | $43,477 |
| RexultiBrexpiprazole | 11 | $16,533 |
| Lisdexamfetamine Dimesylate | 36 | $10,509 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $5,563 |
| Lurasidone Hcl | 29 | $4,685 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 50 | $4,450 |
| Aripiprazole | 33 | $4,099 |
| ViibrydVilazodone Hcl | 12 | $3,961 |
| Vilazodone Hcl | 19 | $3,572 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 81 | $2,917 |
| Paliperidone ErPaliperidone | 13 | $2,773 |
| Bupropion XlBupropion Hcl | 65 | $2,229 |
| Quetiapine Fumarate | 57 | $2,073 |
| Ziprasidone Hcl | 26 | $1,655 |
| Lorazepam | 81 | $1,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $188 | $43,47719 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $50 | $16,53311 claims |
| AbbVieViibryd | $1,512 | $3,96112 claims |
| Almatica Pharma LLCSertraline Hcl | $160 | $12520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.
Other psychiatry in San Clemente
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.